Novel Quantification of Tenofovir Disoproxil Fumarate Adherence in Human Immunodeficiency Virus/Hepatitis B Coinfected Patients With Incomplete Hepatitis B Virus Viral Suppression Reply

被引：0
|
作者：
Boyd, Anders [1 ]
Peytavin, Gilles [2 ,3 ]
Lacombe, Karine [4 ,5 ]
机构：
[1] Inst Pierre Louis Epidemiol & Sante Publ, UMR S 1136, INSERM, Paris, France
[2] Bichat Claude Bernard Hosp, AP HP, Pharmacotoxicol Dept, Paris, France
[3] INSERM, UMR 1137, IAME, Paris, France
[4] St Antoine Hosp, AP HP, Dept Infect & Trop Dis, Paris, France
[5] Univ Paris 06, Sorbonne Univ, UMR S 1136, Inst Pierre Louis Epidemiol & Sante Publ, Paris, France
来源：
HEPATOLOGY | 2016年 / 64卷 / 03期
关键词：
VIREMIA;
D O I：
10.1002/hep.28463
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1000 / 1001
页数：2
相关论文
共 50 条
  • [1] Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression
    Wong, Tammy C.
    Lan, Audrey
    Kiser, Jennifer J.
    Anderson, Peter L.
    Patel, Keyur
    Tillman, Hans
    Naggie, Susanna
    HEPATOLOGY, 2016, 64 (03) : 999 - 1000
  • [2] Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed
    Ristig, MB
    Crippin, J
    Aberg, JA
    Powderly, WG
    Lisker-Melman, M
    Kessels, L
    Tebas, P
    JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (12): : 1844 - 1847
  • [3] Efficacy of tenofovir disoproxil fumarate (TDF) for hepatitis B virus (HBV) in human immunodeficiency virus (HIV) infected patients.
    Benhamou, Y
    Piketty, C
    Katlama, C
    Rozembaum, W
    Neau, D
    Lafeuillade, A
    Rey, D
    Yazdanpanah, Y
    Trimoulet, P
    Fleury, H
    HEPATOLOGY, 2003, 38 (04) : 712A - 713A
  • [4] Management of hepatitis B in patients coinfected with the human immunodeficiency virus
    Lessells, R
    Leen, C
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (05) : 366 - 374
  • [5] Management of hepatitis B in patients coinfected with the human immunodeficiency virus
    R. Lessells
    C. Leen
    European Journal of Clinical Microbiology and Infectious Diseases , 2004, 23 : 366 - 374
  • [6] Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B
    Naoky C. Tsai
    Patrick Marcellin
    Maria Buti
    Mary Kay Washington
    Samuel S. Lee
    Sing Chan
    Huy Trinh
    John F. Flaherty
    Kathryn M. Kitrinos
    Phillip Dinh
    Prista Charuworn
    G. Mani Subramanian
    Edward Gane
    Digestive Diseases and Sciences, 2015, 60 : 260 - 268
  • [7] Viral Dynamics of Hepatitis B Virus DNA in Human Immunodeficiency Virus-1-Hepatitis B Virus Coinfected Individuals: Similar Effectiveness of Lamivudine, Tenofovir, or Combination Therapy
    Lewin, Sharon R.
    Ribeiro, Ruy M.
    Avihingsanon, Anchalee
    Bowden, Scott
    Matthews, Gail
    Marks, Pip
    Locarnini, Stephen A.
    Ruxrungtham, Kiat
    Perelson, Alan S.
    Dore, Gregory J.
    HEPATOLOGY, 2009, 49 (04) : 1113 - 1121
  • [8] Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B
    Tsai, Naoky C.
    Marcellin, Patrick
    Buti, Maria
    Washington, Mary Kay
    Lee, Samuel S.
    Chan, Sing
    Trinh, Huy
    Flaherty, John F.
    Kitrinos, Kathryn M.
    Dinh, Phillip
    Charuworn, Prista
    Subramanian, G. Mani
    Gane, Edward
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (01) : 260 - 268
  • [9] Management of the coinfected patient: Human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C
    Murphy, MJ
    Wilcox, RD
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2004, 328 (01): : 26 - 36
  • [10] Cumulative Tenofovir Exposure Among Patients With Human Immunodeficiency Virus/Hepatitis B Coinfection With Differential Viral Suppression
    Zhang, Helen L.
    Mock, Meredith
    Bushman, Lane
    Anderson, Peter L.
    Kiser, Jennifer J.
    Naggie, Susanna
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (03) : 705 - 708
12345